Orphan drugs and the NHS

BMJ

Volumn 331, Issue 7525, 2005, Pages 1144-1145

  Sheehan, Mark ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DRUG MANUFACTURE; ECONOMICS; HUMAN; NATIONAL HEALTH SERVICE; NOTE; RARE DISEASE; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES; STATE MEDICINE;

EID: 32944471148     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.331.7525.1144-c     Document Type: Letter

References (1)

1. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ 2005; 331: 1016–9. (29 October.)